First Non-Hormonal Treatment for Hot Flashes Approved by FDA

First Non-Hormonal Treatment for Hot Flashes Approved by FDA

In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.

Brisdelle contains 7.5 mg of paroxetine, a selective serotonin reuptake inhibitor (SSRI) that is used at higher doses to treat depression and anxiety disorders. Two randomized, controlled, double-blind studies in women with moderate to severe hot flashes showed that Brisdelle reduced the frequency and severity of hot flashes.

There was a low occurrence of side effects, most commonly nausea. Because paroxetine is also used to treat depression, it will carry a Boxed Warning about the possibility of the medication increasing suicidality in children and young adults.

Hot flashes affect nearly 75% of women in menopause. Historically, hormone therapy with estrogen has been the only approved pharmacologic treatment, but its side effects and risk profile made it unacceptable for many patients.

Loading comments...
Please Wait 20 seconds or click here to close